timothy sykes logo
PSNL Jumps As Personalis Agrees To Tempus AI Buyout Thumbnail
G Google News

PSNL Jumps As Personalis Agrees To Tempus AI Buyout

MATT MONACO•UPDATED AUG. 22, 2026, 11:05 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Personalis Inc. stocks have been trading up by 9.41 percent after upbeat oncology genomics advances fueled strong investor optimism.

What Traders Need To Know

  • Tempus AI is buying Personalis for $16.25 per share, in a deal valuing the company near $1.5B and allowing up to 50% of consideration in cash.
  • Q2 revenue came in at $22.4M versus $16.7M expected, powered by a 199% year-over-year and 33% sequential surge in NeXT Personal MRD test volumes.
  • Management guided to more than 500% clinical revenue growth for the year, tying upside to strategic benefits from the Tempus combination.
  • Several shareholder-rights firms are challenging whether the $16.25 per-share deal undervalues PSNL and whether the board ran a fair sale process.
  • The company will stop issuing guidance and holding earnings calls, signaling that near-term trading is now dominated by deal risk rather than standalone outlook.

Candlestick Chart

Weekly Update Aug 17 – Aug 21, 2026: On Saturday, August 22, 2026 Personalis Inc. stock [NASDAQ: PSNL] is trending up by 9.41%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Personalis sits in a strong strategic niche in MRD and oncology genomics but remains fundamentally loss‑making. Gross margin at 63% is competitive versus diagnostics peers, yet EBIT margin at roughly –154% and ROE near –50% highlight an unsustainable standalone model. Revenue is rebounding (Q2 sales $22.4M, +199% clinical volume; three‑year CAGR positive despite five‑year decline), but operating cash burn of ~$26M in Q2 and negative free cash flow underscore reliance on capital markets or strategic support despite a solid cash position and low leverage.

Technically, the stock has broken out sharply above the $16.25 Tempus deal reference, with the weekly progression from $13.77 to $18.47 showing a powerful, high‑volume upside re‑rating and clear bullish momentum. The dominant trend is now strongly upward, driven by merger‑arbitrage repricing and incremental upside speculation. Key actionable level: $16.25 functions as hard support and stop‑loss anchor; as long as price holds above $16.25 on closing and dips toward $17–17.50 occur on lighter volume, the favorable risk‑reward lies in staying long rather than initiating new shorts.

The Tempus acquisition at $16.25 per share effectively defines downside, while upside is now tied to potential competing bids, deal sweeteners, or deal‑break risk. Multiple law‑firm “fairness” investigations are standard in healthcare M&A and, absent substantive challenges, are unlikely to block closing. Compared with diagnostics peers, PSNL’s growth inflection in MRD is above sector but profitability is materially below. Base case is deal completion near current levels; trading band is $16.25 support and $19–20 resistance, with risk‑skew positive for near‑term holders.

More Breaking News

Quick Financial Overview

Personalis Inc. just shifted from growth story to buyout story. PSNL agreed to be acquired by Tempus AI for $16.25 per share, effectively putting a ceiling on the stock in the near term. At roughly $1.5B implied value net of Tempus’s existing stake, the market now trades PSNL as a merger-arb situation rather than a pure momentum play.

Under the hood, the business is inflecting. Q2 revenue reached $22.4M, well ahead of the $16.7M consensus, thanks to a 199% year-over-year and 33% quarter-over-quarter jump in NeXT Personal MRD clinical testing volumes. Management also guided to more than 500% clinical revenue growth for the year. That growth sits on top of a 63.3% gross margin, but profitability remains deeply negative, with EBIT margin around -153.5% and free cash flow at about -$29.6M for the quarter.

The balance sheet is solid for now. Current ratio of 5.3 and quick ratio of 4.9 show ample liquidity, with $95.8M ending cash and over $212.7M in cash plus short-term investments. Leverage is modest, with total debt-to-equity at 0.13, but returns on equity and assets are sharply negative. Technically, PSNL exploded from the mid-teens to the high teens, with weekly closes climbing from $13.77 to $18.47 and an intraday spike from about $16.66 to $18.89. That pattern tells you the deal headline and earnings beat triggered a fast repricing toward the $16.25 reference and beyond.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”